TAP Licenses Prevacid To Novartis For 2009 Switch
This article was originally published in The Pink Sheet Daily
Executive Summary
TAP plans to continue sale of prescription lansoprazole “at least” until the compound patent expires.
You may also be interested in...
Prevacid, Zyvox, Valcyte Paragraph IV Certifications Filed
The first ANDA with a Paragraph IV certification for TAP's heartburn and GERD therapy Prevacid was filed in December, FDA's list of certification filings indicates
Prevacid, Zyvox, Valcyte Paragraph IV Certifications Filed
The first ANDA with a Paragraph IV certification for TAP's heartburn and GERD therapy Prevacid was filed in December, FDA's list of certification filings indicates
JAMA Study Links Gastric Acid-Suppressing Drugs To Increased Diarrhea Risk
Analysis of UK database shows association between both H2-receptor antagonists and PPIs and increased Clostridium difficile infections.